gsk arexvy news - Search News

GSK, RSV

Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.

YAHOO!Finance · 7h

GSK says RSV vaccine protects against disease over three seasons

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

London South East · 12h

GSK trial proves RSV vaccine efficacy after three full seasons

Arexvy is the world's first approved RSV vaccine and results showed that after a single dose, cumulative efficacy over three full RSV seasons was clinically meaningful.

Reuters · 1d

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.

Seeking Alpha on MSN · 1d

U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report

Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV vaccine. The ruling is part of ongoing litigation between the two drugmakers over their respective RSV vaccines.

11hon MSN

GSK RSV shot 43% effective against severe disease in third year

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

FiercePharma9h

GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

12h

GSK Arexvy protects from RSV over three full seasons

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

McKnight's Long-Term Care News3h

RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

ENDPOINTS NEWS5h

GSK's RSV vaccine Arexvy shows long-term protection in Phase 3 trial

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

13h

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

12h

GSK's Arexvy provides protection over three RSV seasons, trial shows

GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...

10h

GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

13h

GSK Says RSV Vaccine Arexvy Showed Positive Efficacy Data Over Three Seasons

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics